Abstract
There is an extensive literature on the adverse effects of drugs that inhibit gastric acid secretion. This study presents a critical examination of interactions between antisecretory drugs and other compounds, the frequency of serious adverse effects relating to various body systems, the safety of antisecretory drugs in pregnancy, and longer-term safety data from postmarketing surveillance studies. While interactions with some other drugs, alcohol, and certain carcinogens are of potential concern, in practice clinically significant reactions appear to be rare if they occur at all. A small number of major side-effects have been documented, but they occur rarely, and postmarketing surveillance has not detected other longer-term sequelae. Safety of these drugs in pregnancy is not established, as data are so few. It is concluded that antisecretory agents, by comparison with most other classes of drugs, are remarkably well tolerated.
Similar content being viewed by others
References
Lewis JH: Hepatic effects of drugs used in the treatment of peptic ulcer disease. Am J Gastroenterol 82:987–1003, 1987
Gugler R, Allgayer H: Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clin Pharmacokinet 18:210–219, 1990
Black M: Hepatotoxic and hepatoprotective potential of histamine (H2)-receptor antagonists. Am J Med 83:68–75, 1987
Krishna DR, Klotz U Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential. Clin Pharmacokinet 15:205–215, 1988
Smith SR, Kendall MJ: Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions. Clin Pharmacokinet 15:44–56, 1988
Mitchard M, Harris A, Mullinger BM: Ranitidine interactions: A literature review. Pharmacol Ther 32:293–325, 1987
Klotz U, Kroemer HK: The drug interaction potential of ranitidine: An update. Pharmacol Ther 50:233–244, 1991
Somogyi A, Muirhead M: Pharmacokinetic interaction of cimetidine. Clin Pharmacokinet 12:321–366, 1987
Greene W: Drug interactions involving cimetidine-mechanisms, documentation, implications. Q Rev Drug Metab Drug Interact 5:25–51, 1984
Howell JR, Donn KH: Histamine H2-antagonists drug interactions in perspective: Mechanistic concepts and clinical implications. Am J Med 77:57–84, 1984
Baciewicz AM, Baciewicz FA: Effect of cimetidine and ranitidine on cardiovascular drugs. Am Heart J 118:144–154, 1989
Sax MJ: Clinically important adverse effects and drug interactions with H2-receptor antagonists: An update. Pharmacotherapy 7:110S-115S, 1987
Reilly CS, Biollaz J, Koshakji RP, Wood AJ: Enprostil, in contrast to cimetidine, does not inhibit propranolol metabolism. Clin Pharmacol Ther 40:37–41, 1986
Klotz U, Reimann J: Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. Eur J Clin Pharmacol 18:517–520, 1980
Sachs G, Kowalsky SF: Acetaminophen interaction with cimetidine and ranitidine: A critical analysis of the literature. Adv Ther 5:257–272, 1988
Heagerty AM, Donovan MA, Castleden CM, Pohl JF, Patel L, Hedges A: Influence of cimetidine on pharmacokinetics of propranolol. BMJ 282:1917–1919, 1981
Kirch W, Janisch HD, Heidemann H, Ramsch K, Ohnhaus EE: Effect of cimetidine and ranitidine on the pharmacokinetics and the antihypertensive action of nifedipine. Dtsch Med Wochenschr 108:1757–1761, 1983
Winship LC, McKenney JM, Wright JT, Wood JH, Goodman RP: The effect of ranitidine and cimetidine on single dose diltiazem pharmacokinetics. Pharmacotherapy 5:16–19, 1985
Smith MJ, Benyunes MC, Björnsson TD, Shand DG, Pritchett ELC: Influence of cimetidine on verapamil kinetics and dynamics. Clin Pharmacol Ther 36:551–554, 1984
Feeley J, Wilkinson GR, McAllister CB, Wood AJB: Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med 96:593–594, 1982
Somogyi A, Bochner F: Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. Br J Clin Pharmacol 18:175–181, 1984
Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L: Slow omeprazole metabolisers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12:415–416, 1990
Toon S, Hopkins KJ, Garstang FM, Rowland M: Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. J Clin Pharmacol 32:165–172, 1987
Gaska JA, Tietze KJ, Rocci ML, Vlasses PH: Theophylline pharmacokinetics—effect of continuous versus intermittent cimetidine IV infusion. J Clin Pharmacol. 31:668–672, 1991
Chanery RJ, Ayrton A, Oldham HC, Norman BJ, Standring P: The interaction of omeprazole with rat liver cytochrome P-450-mediated monooxygenase reactionsin vitro andin vivo. Biochem Pharmacol 37:1407–1414, 1986
Henry DA, Somerville KW, Kitchingman G, Langman MJS: Omeprazole: Effects on oxidative drug metabolism. Br J Clin Pharmacol 18:195–200, 1984
Oosterhuis B, Jonkman JHG: Omeprazole: Pharmacology, pharmacokinetics and interactions. Digestion 44(suppl 1): 9–17, 1989
Gugler R, Jensen JC: Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoinin vivo and 7-ethoxycoumarinin vitro. Gastroenterology 89:1235–1241, 1985
Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P: Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Pharmacol 39:51–54, 1990
Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P: Effects of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 47:79–85, 1990
Sutfin T, Balmer K, Boström H, Eriksson S, Höglund P, Paulsen O: Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 11:176–184, 1989
Andersson T, Lagerström P, Unge P: A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit 12:329–333, 1990
Prichard PJ, Walt RP, Kitchingman GK, Somerville KW, Langman MJS, Williams J, Richens A: Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 24:543–545, 1987
Gugler R, Jensen JC: Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolismin vivo. Pharmacol Ther 33:133–137, 1987
Geneve J, Bocquentin M, Taburet AM, Simoneau G, Caulin C, Singlas E: Effect of omeprazole on theophylline metabolism in healthy subjects. Gastroenterology 100:A69, 1991
Andersson T, Bergstrand R, Cederberg C, Eriksson S, Lagerström P, Skånberg I: Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology 101:943–947, 1991
Andersson T, Lundborg P, Regårdh CG: Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol. Eur J Clin Pharmacol 40:61–65, 1991
Henry D, Brent P, Whyte I, Mihaly G, Devenish-Meares S: Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol 33:369–373, 1987
Bannister J, Noble DW, Lamont M, Scott DB: Lack of effect of omeprazole on the disposition of lignocaine and its active metabolite in healthy subjects. Anaethesia 49:497–500, 1994
Ching MS, Elliott SL Stead CK, Murdoch RT, Devenish-Meares SE, Morgan DJ, Smallwood RA: Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. Aliment Pharmacol Ther 5:523–531, 1991
Blohmé I, Andersson T, Idström JP: No interaction between omeprazole and cyclosporine. Br J Clin Pharmacol 35:155–160, 1993
Andersson T: Drug interaction studies with omeprazole—a review. Clin Pharmacokinet 21:195–212, 1991
Cohen AF, Kroon R, Schoemaker HX, Hoogkamer JFW, Van Vliet-Verbeek A: Influence of gastric acidity on the bioavailability of digoxin. Ann Intern Med 115:540–545, 1991
Sohn DR, Kobayashi K, Chiba K, Lee K-H, Shin S-G, Ishizaki T: Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers ofS-mephenytoin 4′-hydroxylation recruited from an oriental population. J Pharmacol Exp Ther 262:1195–1202, 1992
Jensen JC, Gugler R: Cimetidine interaction with liver microsomesin vitro andin vivo. Involvement of an activated complex with cytochrome P-450. Biochem Pharmacol 34:2141–2146, 1985
Testa B, Jenner P: Inhibitors of cytochrome P-450s and their mechanism of action. Drug Metab Rev 12:1–117, 1981
Murray M, Wilkinson CF: Interactions of nitrogen heterocycles with cytochrome P-450 and monooxygenase activity. Chem Biol Interact 50:267–275, 1984
Ortiz de Montellano PR, Reich NO: Inhibition of cytochrome P-450 enzymes.In Cytochrome P-450: Structure, Mechanism and Biochemistry. de Montellano O (ed.) New York, Plenum Press, pp 274–275, 1986
Rogerson TD, Wilkinson CF, Hetarski K: Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes. Biochem Pharmacol 26:1039–1042, 1977
Rodrigues AD, Lewis DFV, Ioannides C, Parke DV: Spectral and kinetic studies of the interaction of imidazole antifungal agents with microsomal cytochromes P-450. Xenobiotica 17:1315–1327, 1987
Morita K, Ono T, Shimakawa H: Inhibition of testosterone biosynthesis in testicular microsomes by various imidazole drugs. Comparative study with ketoconazole. J Pharmacobiodyn 13:336–343, 1990
Ritter JK, Franklin MR: High magnitude hepatic cytochrome P-450 induction by anN-substituted imidazole antimycotic, clotrimazole. Biochem Pharmacol 36:2783–2787, 1987
Molowa SA, Thomas DT, Levin PE, Guzelian W, Guzelian PS: Coinduction of multiple hepatic cytochrome P-450 proteins and their mRNAs in rats treated with imidazole antimycotic agents. Mol Pharmacol 35:279–285, 1989
Skånberg I, Boström H, Löfberg I, Suffin T: Effect of omeprazole on the metabolism of other drugs—in vivo and in vitro data. IInd international ISSX Meeting, Kobe, Japan, May 16–20, 1988 (abstract)
Schenkman JB, Sligar SG, Cinti DL: Substrate interactions with cytochrome P-450.In Hepatic Cytochrome P-450 Monooxygenase System. Schenkman JB, Kupfer D (eds). International Encyclopedia of Pharmacology and Therapeutics. New York, Pergamon Press, pp 587–615, 1982
Ioannoni B, Mason SR, Reilly PE, Winzor DJ: Evidence of induction of hepatic microsomal cytochrome P-450 by cimetidine: Binding and kinetic studies. Arch Biochem Biophys 247:372–383, 1986
Diaz D, Fabre I, Daujat M, Saint Aubert B, Bories P, Michel H, Maurel, P: Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 99:737–747, 1990
Distelrath LM, Reilly PEB, Martin MV, Davis GG, Wilkinson R, Guengerich FP: Purification and characterization of the human liver cytochromes P450 involved in debrisoquine 4-hydroxylation and phenacetinO-deethylase, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260:9057–9067, 1985
Guengerich FP, Dannan GA, Wright ST, Martin MV, Kaminsky LS: Purification and characterization of liver microsomal cytochromes P450: Electrophoresis, spectral, catalytic and immunochemical properties and inducibility of eight enzymes isolated from rats treated with phenobarbital or β-nephthoflavone. Biochemistry 21:19–30, 1982
McDonnell WM, Scheiman JM, Traber PG: Induction of cytochrome P4501A genes (CYP1A) by omeprazole in the human alimentary tract. Gastroenterology 103:1509–1516, 1992
Robson RA, Miners JO, Matthews AP, Stupans I, Meller D, McManus ME, Birkett DJ: Characterisation of theophylline metabolism by human liver microsomes. Biochem Pharmacol 37:1651–1659, 1988
Seasardic D, Boobis AR, Murray BP, Murray S, Segura J, DeLa Torre R, Davies DS: Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 29:651–663, 1990
Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF Human cytochrome P450PA (P450 1A2), the phenacetinO-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine andN-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86:7696–7700, 1989
Rost KL, Brösicke H, Brokmöller J, Scheffler M, Helge H, Roots I: Increase of cytochrome P4501A2 activity by omeprazole: Evidence by the13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 52:170–180, 1992
Parkinson A, Hurwitz A: Omeprazole and the induction of human cytochrome P-450. A response to concerns about potential adverse effects. Gastroenterology 100:1157–1164, 1991
Seitz HK, Veith S, Czygan P, Bosche J, Simon B, Gugler R, Kommerell B:In vivo interactions between H2-receptor antagonists and ethanol metabolism in man and in rats. Hepatology 4:1231–1234, 1984
Feely J, Wood AJ: Effects of cimetidine on the elimination and actions of ethanol. JAMA 247:2819–2821, 1982
DiPadova C, Roine R, Frezza M, Gentry RT, Baraona E, Leiber CS: Effects of ranitidine on blood alcohol levels after ethanol ingestion. Comparison with other H2-receptor antagonists. JAMA 267:83–86, 1992
Caballeria J, Baraona E, Rodamilans M, Lieber CS: Effects of cimetidine on gastric alcohol dehydrogenase activity and blood ethanol levels. Gastroenterology 96:388–392, 1989
Frezza M, Di-Padova C, Pozzato G, Terpin M, Barona E, Lieber CS: High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 322:95–99, 1990
Tanaka E, Nakamura K: Effects of H2-receptor antagonists on ethanol metabolism in Japanese volunteers. Br J Clin Pharmacol 26:96–99, 1988
Johnson KI, Fenzl E, Hein B: The effect of cimetidine on the metabolism and effects of alcohol. Arzneimittelforschung 34:734–736, 1984
Northop I, Kneip M, Oehmichen M, Staak M, Iffland R, Kaferstein H: The effect of the administration of H2-receptor blockers on alcohol kinetics and psychophysical fitness. Beitr Gesch Med 44:1–4, 1986
Dobrilla G, de Pretis G, Piazzi L, Chilovi F, Comberlato M, Valentini M, Pastorino A, Vallaperta P: Is ethanol metabolism affected by oral administration of cimetidine and ranitidine at therapeutic doses? Hepatogastroenterology 31:35–37, 1984
Webster LK, Jones DB, Smallwood RA: Influence of cimetidine and ranitidine on ethanol pharmacokinetics. Aust NZ J Med 15:359–360, 1985
Fraser AG, Prewett EJ, Hudson M, Sawyerr AM, Rosalki SB, Pounder RE: The effect of ranitidine, cimetidine or famotidine on low-dose post-prandial alcohol absorption. Aliment Pharmacol Ther 5:263–272, 1991
Palmer RH: Cimetidine and alcohol consumption. Gastroenterology 97:1066–1067, 1989
Caballeria J, Baraona E, Rodamilans M, Lieber CS: Reply to “Cimetidine and alcohol consumption.” Gastroenterology 97:1066–1067, 1989
Palmer RH, Frank WO, Nambi P, Wetherington JO, Fox MJ: Effects of various concomitant medications on gastric alcohol dehydrogenase and the first-pass metabolism of ethanol. Am J Gastroenterol 86:1749–1755, 1991
Raufman JP, Notar-Francesco V, Raffaniello RD, Straus EW: Histamine-2 receptor antagonists do not alter serum ethanol levels in fed, nonalcoholic men. Ann Intern Med 118:488–494, 1993
Jonsson KA, Jones AW, Boström H, Andersson T: Lack of effect of omeprazole, cimetidine and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. Eur J Clin Pharmacol 42:209–212, 1992
Fraser AG, Hudson M, Sawyerr AM, Smith MS, Rosalki SB, Pounder RE: Ranitidine, cimetidine, famotidine have no effect on post-prandial absorption of ethanol 0.8 g/kg taken after an evening meal. Aliment Pharmacol Ther 6:693–700, 1992
Roine R, Hernandez-Munoz R, Baraona E, Greenstein R, Leiber CS: Effect of omeprazole on gastric first-pass metabolism of ethanol. Dig Dis Sci 37:891–896, 1992
Fraser AG, Hudson M, Sawyerr AM, Smith MS, Sercombe J, Rosalki SB, Pounder RE: Ranitidine has no effect on postbreakfast ethanol absorption. Am J Gastroenterol 88:217–221, 1993
Hough LB, Green JP: Histamine receptors.In Cellular Receptors for Hormones and Neurotransmitters. Schulster D, Levitzki (eds). New York, John Wiley & Sons, pp 287–290, 1980
Haas HL, Konnerth A: Histamine and noradrenaline decrease calcium-activated potassium conductase in hippocampal pyramidal cells. Nature 302:432–434, 1983
Kagevi I, Wahlby L: CSF concentrations of ranitidine. Lancet 1:164–165, 1985
Kagevi I, Thorhallson E, Wahlby L: Cerebrospinal fluid concentration of famotidine. Scand J Gastroenterol 22:27, 1987
Jonsson KA, Eriksson SE, Kagevi I, Norlander B, Bodemar G, Walan A: No detectable concentrations of oxmetidine but measurable concentrations of cimetidine in cerebrospinalfluid (CSF) during multiple dose treatment. Br J Clin Pharmacol 17:781–782, 1984
Schentag JJ, Cerra FB, Calleri G, DeGlopper E, Rose JQ, Bernhard H: Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. Lancet 1:177–181, 1979
Kimelblatt BJ, Cerra FB, Calleri G, Berg MJ, McMillen MA, Schentag JJ: Dose and serum concentration relationship in cimetidine-associated mental confusion. Gastroenterology 78:791–795, 1980
Berg MJ, Schentag JJ: Cimetidine distribution in human serum, tissue and cerebrospinal fluid. Clin Pharmacol Ther 25:214, 1979
Lakoski JM, Aghajanian GK: Effects of histamine H1- and H2-receptor antagonists on the activity of serotonin-containing neurons in the dorsal raphe. J Pharmacol Exp Ther 227:517–523, 1983
Sibilia V, Netti C, Guidobono F, Pagani F, Pecile A: Cimetidine-induced prolactin release: Possible involvement of GABA-ergic system. Neuroendocrinology 40:189–192, 1985
Penston J, Wormsley KG: Adverse reactions and interactions with H2-receptor antagonists. Med Toxicol 1:192–216, 1986
Bories P, Michel H, Duclos B, Beraud JJ, Mirouze J: Use of ranitidine, without mental confusion, in patients with renal failure. Lancet 2:755, 1980
Hubain PP, Sobolski J, Mendlewicz J: Cimetidine-induced mania. Neuropsychobiology 8:223–224, 1982
Crowder MK, Pate JK: A case-report of cimetidine-induced depressive syndrome. Am J Psychiatry 137:1451, 1980
Edmonds ME, Ashford RFU, Brenner MK, Saunders A: Cimetidine: Does neurotoxicity occur? Report of 3 cases. J R Soc Med 72:172–175, 1979
Titus JP: Cimetidine-induced mania in depressed patients. J Clin Psychiatry 44:267–268, 1983
Epstein CM: Ranitidine and confusion. Lancet 1:1071, 1984
Price W, Coli L, Brandstetter RD, Gotz VP: Ranitidine-associated hallucinations. Eur J Clin Pharmacol 29:375–376, 1985
Reid SR, Bayliff CD: The comparative efficiency of cimetidine and ranitidine in controlling gastric pH in critically ill patients. Can Anaesth Soc J 33:287–293, 1986
Barth HO, Berg P, Brunner G, Dammann HG, Friedl W, Franken FH, Greiner L, Groitl J, Mockel W, Muller P: Ranitidine and cimetidine in stress-ulcer prophylaxis: a comparative multicenter study. Lang Archir Chir 362:131–138, 1984
Wildeman RA: Focus on misoprostol: Review of worldwide safety data. Clin Invest Med 10:243–245, 1987
Bianchi-Porro G, Parente F: Side effects of anti-ulcer prostaglandins: An overview of the worldwide clinical experience. Scand J Gastroenterol 164(suppl):224–231, 1989
Jacquemier JM, Lassoued S, Laroche M, Mazieres B: Neurosensory adverse effects after phenylbutazone and misoprostol combined treatment. Lancet 2:1283, 1989
Nelis GF: Safety profile of omeprazole. Adverse events with short-term treatment. Digestion 44(suppl 1):68–76, 1989
Sölvell L: The clinical safety of omeprazole. Scand J Gastroenterol 166(suppl):106–113, 1989
Ruffenach SJ: Acute interstitial nephritis due to omeprazole. Am J Med 93:472–473, 1992
Christensen CK, Morgensen CE, Sörensen FA: Renal function and cimetidine. Scand J Gastroenterol 16:129–134, 1981
Yeung CK, Wong KL, Ng MT, Lai CL: Effects of cimetidine, ranitidine and antacid on renal function. Clin Ther 6:620–624, 1984
Kaye WA, Passero MA, Solomon RJ, Johnson LA: Cimetidine-induced interstitial nephritis with response to prednisolone therapy. Arch Intern Med 143:811–812, 1983
Pitone JM, Santoro JJ, Biondi RJ, Chiesa JC, Pecora AA: Cimetidine-induced acute interstitial nephritis. Am J Gastroenterol 77:169–171, 1982
Watson AJS, Dalbow MH, Stachura I, Fragola JS, Rubin MF, Watson RM, Bourke E: Immunologic studies in cimetidine-induced nephropathy and polymyositis. N Engl J Med 308:142–145, 1983
Rowley-Jones D, Flind AC: Cimetidine-induced renal failure. BMJ 285:1422–1423, 1982
Gill M, Sanyal SN, Sareen ML: Effect of histamine H2-receptor antagonist ranitidine on renal brush border and basolateral membranes. Res Exp Med 190:345–356, 1990
Wingo CS: Active proton secretion and potassium absorption in the rabbit outer medullary collecting duct: Functional evidence for H-K-ATPase. J Clin Invest 84:361–365, 1989
Garg LC, Narang N: Ouabain-insensitive K-adenosine triphosphatase in distal nephron segments of the rabbit. J Clin Invest 81:1204–1208, 1988
Doucet A, Marsy S: Characterization of K-ATPase activity in distal nephron stimulation by potassium depletion. Am J Physiol 253:F418-F423, 1987
Wingo CS, Madsen KM, Smolka A, Tisher CC: H-K-ATPase immunoreactivity in cortical and outer medullary collecting duct. Kidney Int 38:985–990, 1990
Howden DW, Reid JL: Omeprazole, a gastric proton pump inhibitor: Lack of effect on renal handling of electrolytes and urinary acidification. Eur J Clin Pharmacol 26:639–640, 1984
Descotes J: Drug-Induced DisordersIn Dukes, MNG (ed). Amsterdam, Elsevier, 1990
Kumar A: Cimetidine an immunomodular. DICP 24(3):289–295, 1990
Jorizzo JL, Sams WM Jr, Jegasothy BV, Olansky AJ: Cime-tidine as an immunomodulator: Chronic mucocutaneous candidiasis as a model. Ann Intern Med 92:192–195, 1980
White WB, Ballow M: Modulation of suppressor-cell activity by cimetidine in patients with common variable hypogammaglobulinemia. N Engl J Med 312:198–202, 1984
Ahonen J, Paimela H, Kauste H, Häyry P, Eklund B, Pettersson E: Ranitidine and cimetidine in renal transplantation: A clinical trial. Int J Tissue React 5:373–378, 1983
Jacob ET, Papa M: Cimetidine and renal allograft rejection. Isr J Med Sci 19:161–164, 1983
Hawkins RA, Eckhoff PJ Jr, McCarter DK, Harmon CE: Cimetidine and polymyositis. N Engl J Med 309:187–188, 1983
Brockmeyer NH, Kreuzfelder E, Mertins L, Chalabi N, Kirch W, Scheiermann N, Goos M, Ohnhaus EE: Immunomodulatory properties of cimetidine in ARC patients. Clin Immunol Immunopathol 48:50–60, 1988
Descotes J, Tedone R, Eureux JCI: Effects of cimetidine and ranitidine on delayed-type hypersensitivity. Immunopharmacology 6:31–35, 1983
Tomioka K, Yamada T, Tachikawa S: Effects of famotidine (YM-11170), an H2-receptor antagonist, onin vivo immediate and delayed type hypersensitivity reactions and antibody formation. Drugs Exp Clin Res 9:881–889, 1983
Byron JW: Mechanism for histamine-H2-receptor induced cell cycle changes in the bone marrow stem cell. Agents Actions 7:209–213, 1979
Pixley JS, MacKintosch FR, Sahr EA, et al: Mechanism of ranitidine associated anemia. Am J Med Sci 297:369–371, 1989
Aymard FP, Aymard B, Netter P, Bannworth B, Trochot P, Streiff, F: Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol 3:430–448, 1988
Brenner LO: Agranulocytosis and ranitidine. Ann Intern Med 104:896–897, 1986, (letter)
Chang HU, Morrison SL: Bone marrow suppression associated with cimetidine. An Intern Med 91:580, 1979
McGuigan JE: Side effects of histamine2-receptor antagonists. Clin Gastroenterol 12:819–838, 1983
Rowley-Jones D, Flind AC: Continuing evaluation of the safety of medicine.In Cimetidine in the 80s. Baron JH (ed). Bath, The Pitman Press, 1982, p 261
Posnett DN, Stein RS, Graber SE, Krantz SB: Cimetidineinduced neutropenia. A possible dose related phenomenon. Arch Intern Med 139:584–586, 1979
Agura ED, Vila E, Petersen FB, Shields AF, Thomas ED: The use of ranitidine in bone marrow transplantation. A review of 223 cases. Transplantation 46:53–56, 1988
Amos RJ, Kirk B, Amess JA, Jones AL, Hinds CJ: Bone marrow hypoplasia during intensive care: Bone marrow culture studies implicating ranitidine in the suppression of haemopoiesis. Hum Toxicol 6:503–506, 1987
Idvall J: Cimetidine-associated thrombocytopenia. Lancet 2:159, 1979
Isaacs JS: Cimetidine and thrombocytopenia. BMJ 280:294, 1980
Van Thiel DH, Gavaler JS, Smith WI Jr, Paul G: Hypothalamic-pituitary-gonadal dysfunction in men using cimetidine. N Engl J Med 300:1012–1015, 1979
Wang C, Lai CL, Lam KC, Yeung KK: Effect of cimetidine on gonadal function in man. Br J Clin Pharmacol 13:791–794, 1982
Bohnet HG, Riley AJ: An investigation of the effect of oral ranitidine treatment on hypothalamic-pituitary-gonadal and hypothalamic-pituitary-adrenal function in male and female volunteers.In The Clinical Use of Ranitidine. Misiewicz JJ, Wormsley K (eds). Oxford, Medicine Publishing Foundation Series 5, 1982, pp 69–76.
Van Thiel DH, Gavaler JS, Heyl A, Susen B: An evaluation of the anti-androgen effects associated with H2-antagonist therapy. Scand J Gastroenterol 136(suppl):24–28, 1987
Bianchi-Porro G, Ragni G, Ruspa M, Petrillo M, Barattini G: Long-term treatment with cimetidine does not essentially affect the hypothalamic-pituitary-gonadal axis in man. Hepatogastroenterology 32:77–80, 1985
Wang C, Wong KL, Lam KD, Lai CL: Ranitidine does not affect gonadal function in man. Br J Clin Pharmacol 16:430–432, 1983
Funder JW, Mercer JE: Cimetidine, a histamine H2-receptor antagonist, occupies androgen receptors. J Clin Endocrinol Metab 48:189–191, 1979
Scobie IN, Saunders J, Barnes GD, Hoad J, Wheeler MJ, Lowry C, Sonksen PH, Amphlett G, Riley AJ: A comparative study of the effects of ranitidine and cimetidine on carbohydrate tolerance, growth hormone secretion and the hypothalamic-pituitary-gonadal axis in man. Curr Med Res Opin 10:285–290, 1986
Bohnet HG, Griewe M, Hander JP, Aragona C, Schneider HP: Effects of cimetidine on prolactin, LH and sex steroid secretion in male and female volunteers. Acta Endocrinol 88:428–434, 1978
Carlson HE, Ippoliti AF, Swerdloff RS: Endocrine effects of acute and chronic cimetidine administration. Dig Dis Sci 26:428–432, 1981
Valk TW, England BG, Marshall JC: Effects of cimetidine on pituitary function: Alterations in hormone secretion profiles. Clin Endocrinol 15:139–149, 1981
Colle M, Rudeas E, Cazenave J, Auzeric J, Basilisco G, Camboni G, Manara L: Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine. Eur J Clin Pharmacol 35:529–534 1988
Lardinois CK, Mazzaferri EL: Cimetidine blocks testosterone synthesis. Arch Intern Med 145:920–922, 1985
Knigge U, Dejgaard A, Wollesen F, Ingersley O, Bennett P, Christiansen PM: The acute and long term effect of the H2-receptor antagonists cimetidine and ranitidine on the pituitary-gonadal axis in man. Clin Endocrinol 18:307–313, 1983
Nelis GF: The effect of oral cimetidine on the basal and stimulated values of prolactin, thyroid stimulating hormone, follicle stimulating hormone and luteinizing hormone.In H2-Antagonists. Torsoli A, Lucchelli PE, Brimblecombe RW, (eds). Amsterdam, Excerpta Medica, 1980, pp. 192–197
Corinaldesi R, Pasquali R, Paternico A, Stranghellini V, Paparo GF, Ricci-Maccarini M, Barbara L: Effects of short-and long-term administrations of famotidine and ranitidine on some pituitary, sexual and thyroid hormones. Drugs Exp Clin Res 13:647–654, 1987
Callaghan JT, Bergström RF, Rubin A, Chernish S, Crabtree R, Knadler MP, Obermever B, Offen WW, Schneck DW, Aronoff G, Lasseter KC: A pharmacokinetic profile of nizatidine in man. Scand J Gastroenterol 22(suppl 136):9–17, 1987
Jensen RT, Collen MJ, Pandol SJ, Allende HD, Raufman JP, Bissonnette BM, Duncan WC, Durgin PL, Gillin JC, Gardner JD: Cimetidine induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med 308:881–887, 1983
Spence RW, Celestin LR: Gynaecomastia associated with cimetidine. Gut 20:154–157, 1979
Lindquist M, Edwards IR: Endocrine adverse effects of omeprazole. BMJ 305:451–452, 1992
Knigge U, Wollesen F, Dejgaard A, Thuesen B, Christiansen PM: Comparison between dose-responses of prolactin, thyroid stimulating hormone and growth hormone to two different histamine H2-receptor antagonists in normal men. Clin Endocrinol 15:585–592, 1981
Delle Fave GF, Tamburrano F, De Magistris L, et al: Variations in serum prolactin following cimetidine treatment for peptic ulcer disease. Rendic Gastroenterol 9:142–143, 1977
Majumdar SK, Thomson AD, Shaw GK: Cimetidine and serum prolactin BMJ 1:409, 1978
Burland WL, Gleadle RI, Lee RM, Rowley-Jones D, Groom GV: Prolactin responses to cimetidine. Br J Clin Pharmacol 7:19–21, 1979
Caldara R, Bierti L, Barbieri C, Cambielli M, Romussi M, Ferrari C: Stimulation of prolactin-release by intravenous cimetidine: A dose response study. J Endocrinol Invest 2:79–81, 1979
Carlson HE, Ippoliti AF: Cimetidine, a H2-antihistamine, stimulates prolactin secretion in man. J Clin Endocrinol Metab 45:367–370, 1977
Gonzalez-Villapando C, Szabo M, Frohman LA: Central nervous system mediated stimulation of prolactin secretion by cimetidine, a histamine H2-receptor antagonist: Impaired responsiveness in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia. J Clin Endocrinol Metab 51:1417–1424, 1980
Hegarty JE, Summers K, Cone AM, Jenkins DR, Wood JR: Effect of 800 mg cimetidine and 300 mg ranitidine on serum prolactin. Gastroenterology 88:1415, 1985
Lombardo L: Hyperprolactinemia: Ranitidine revised adverse effect. Ital J Gastroenterol 17:160, 1985
Peden NR, Boyd EJS, Browning MCK, Saunders JAB, Wormsley KG: Effects of two histamine H2-receptor blockingdrugs on basal levels of gonadotrophins, prolactin, testosterone and oestradiol-17β during treatment of duodenal ulcer in male patients. Acta Endocrinol 96:564–568, 1981
Robins AH, McFayden ML: Effect of the new H2-receptor antagonist ranitidine on plasma prolactin levels in duodenal ulcer patients. J Pharm Pharmacol 33:615–616, 1981
Knigge U, Wollesen F, Dejgaard A, Larsen K, Christiansen PM: The effect of histamine stimulation and H2-receptor inhibition on the pituitary prolactin and ACTH release and on cortisol secretion in human males. Horm Metab Res 15:89–91, 1983
Pasquali R, Corinaldesi R, Patrono D, Capelli M, Stranghellini V, Melchionda N, Barbara L, Labo G: Effect of intravenous ranitidine on serum prolactin (PRL): Evidence for a sex difference. Gastroenterology 84:1271, 1983
Hayakawa A, Che K, Miyoshi A, Harawara S, Miwa T, Makabatake T: Properties of famotidine in relation to safety. Ital J Gastroenterol 16:174–176, 1984
Savarino V, Giusti M, Scalabrini P, Bessarione D, Magnolia MR, Granziera L, Celle G: Endocrine functions in man after long-term famotidine therapy. Dig Dis Sci 31:PS378, 1986
Franceschini R, Marabini A, Cataldi A, Salvemini M, Barrecca T, Rolandi E: Famotidine effects on prolactin, growth hormone, and thyrotropin pituitary secretion in man. Curr Ther Res 42:653–657, 1987
Usai P, Atzeni E, Zucca G, Loviselli A, Cherchi MV, Balzano S, Boy MF, Balestrieri A: Effects of the oral administration of famotidine on basal prolactin serum levels. Acta Toxicol Ther 7:57–64, 1986
Riley AJ, Maconochie J: Effect of histamine H2-receptor antagonists on vasopressin and aldosterone secretion. Acta Endocrinol 97(suppl 242):A316, 1981
Pomare EW, McFadyen ML: Hyperosmolar non-ketotic diabetes and cimetidine. Lancet 1:1202, 1978 (letter)
Londong W, Londong V, Cederberg C, Steffen H: Doseresponse study of omeprazole on meal-stimulated gastric acid secretion and gastrin release. Gastroenterology 85:1373–1378, 1983
Müller P, Seitz HK, Simon B, et al: Vierwochige Omeprazolgabe: Einfluss auf Saureverhalten und basale Hormonspiegel. Z Gastroenterol 22:236–240, 1984
Howden CW, Kenyon CJ, Beastall GH, Reid JL: Inhibition by omeprazole of adrenocortical response to ACTH: Clinical studies and experiments on bovine adrenal cortexin vitro. Clin Sci 70:99–102, 1986
MacGilchrist AJ, Howden CW, Kenyon CJ, Beastall GH, Reid JL: The effects of omeprazole on endocrine function in man. Eur J Clin Pharmacol 32:423–425, 1987
Röhss K, Bergstrand R, Cederberg C, Heggelund A: Effect of intravenous omeprazole on basal and stimulated cortisol and 11-deoxycortisol levels in healthy subjects. Gastroenterology 98:A114, 1990
Allen JM, Adrian TE, Webster J, Howe A, Bloom SR: Effect of single dose of omeprazole on the gastrointestinal peptide response to food. Hepatogastroenterology 31:44–46, 1984
Zuchner H: Cholestatische Hepatose unter Cimetidine. Dtsch Med Wochenschr 102:1788–1789, 1977 (letter)
Villeneuve JP, Warner HA: Cimetidine hepatitis. Gastroenterology 77:143–144, 1979.
Lilly JR, Hitch DC, Javitt NB: Cimetidine cholestatic jaundice in children. J Surg Res 24:384–387, 1978
Lorenzini I, Jezequel AM, Orlandi F: Cimetidine-induced hepatitis. Electron microscopic observations and clinical pattern of liver injury Dig Dis Sci 26:275–280, 1981
Delpre G, Kadish U, Livni E: Hepatitis following cimetidine administration. Am J Med Sci 282:153–156, 1982
Adverse Drug Reaction Committee: Cimetidine. Med J Aust 1:394, 1980
Ruiz Del Arbol L, Moreira V, Moreno A, Hernández Ranz F, Cano A, García Plaza A: Bridging hepatic necrosis associated with cimetidine. Am J Gastroenterol 74:267–269, 1980
Van Steenbergen W, Vanstapel MJ, Desmet V, Van Kerckvoorde, L, De Keyzer R, Brijs R, Fevery J, De Groote J: Cimetidine-induced liver injury. Report of three cases. J Hepatol 1:359–368, 1985
Schwartz JT, Gyorkey F, Graham DY: Cimetidine hepatitis. J Clin Gastroenterol 8:681–686, 1986
Porter JB, Jick H, Perera DR, Ylvisaker JT, Hunter JR: Long-term follow-up study of cimetidine. Pharmacotherapy 83:68–75, 1984
Dobbs JH, Muir JG, Smith RN: H2-antagonists and hepatitis. Ann Intern Med 105:803, 1986 (letter)
Takeuchi M, Kaga M, Kiguchi M, Iwata M, Yamaguchi M, Shimpo K, Tanabe T: Chronic toxicity study of ranitidine hydrochloride orally administered in rat. J Toxicol Sci 8:(suppl 1):25–49, 1983
Barr GD, Piper DW: Possible ranitidine hepatitis. Med J Aust 2:241, 1981
Black M, Scott WE Jr, Kanter R: Possible ranitidine hepatoxicity. Ann Intern Med 101:208–210, 1984
Souza Lima MA: Hepatitis associated with ranitidine. Ann Intern Med 101:207–208, 1984
Zimmerman HJ, Jacob L, Bassan H, Gillespie J, Lukacs L, Abernathy CO: Effects of H2-blocking agents on hepatocytes in vitro: Correlation with potential for causing hepatic disease in patients. Proc Soc Exp Biol Med 182:511–514, 1986
Boyd PT, Lepre F, Dickey JD: Chronic active hepatitis associated with cimetidine. BMJ 298:324–325, 1989
Kanashima R, Nagasue N, Furusawa M, Inokuchi K: Inhibitory effect of cimetidine on liver regeneration after two-thirds hepatectomy in rats. Am J Surg 146:293–298, 1983
Kanashima R, Nagasue N, Sakato K: Ranitidine as an inhibitor of liver regeneration. Am J Surg 149:223–227, 1985
Lee S-D, Wang J-Y, Cho C-H, Wu J-C, Lu R-H, Lai K-H, Tsai Y-T, Lo K-J: Effects of H2-receptor antagonists on liver after partial hepatectomy or carbon tetrachloride induced hepatic injury. Scand J Gastroenterol 21:984–990, 1986
Nagasue N, Yukaya H, Ogawa Y, Sasaki Y, Hirose S: Prophylaxis of upper gastrointestinal bleeding with cimetidine in patients undergoing partial hepatectomy. Ann Chir Gynaecol 73:6–10, 1984
Feeley J, Wilkinson GR, Wood AJJ: Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 304:692–695, 1981
Feely J, Guy E: Ranitidine also reduces liver blood flow. Lancet 2:169, 1982 (letter)
Ohnishi K, Saito M, Nomura F, Okuda K, Suzuki N, Ohtsuki T, Goto N, Takashi M: Effect of famotidine on hepatic hemodynamics and peptic ulcer. Am J Gastroenterol 82:415–418, 1987
Burroughs AK, Walt RP, Dunk AA: Effect of cimetidine on portal hypertension in cirrhotic patients. BMJ 284:1159–1160, 1982
Dunk AA, Jenkins WJ, Burroughs AK, Walt RP, Osuafor TOK, Sherlock S, Mackie S, Dick R: The effect of ranitidine on the plasma clearance and hepatic extraction of indocyanine green in patients with chronic liver disease. Br J Clin Pharmacol 16:117–120, 1983
Arditi M, Cravetto C, Molino G, Pera A, Ponti V: The effect of chronic treatment with gastric antisecretory drugs on functional liver plasma flow. Gastroenterology 84:1092, 1983
Ohnishi K, Kakayama T, Saito M, Hatano H, Nomura F, Iida S, Okuda K: Effects of cimetidine and ranitidine on splanchnic hemodynamics in patients with chronic liver disease. Am J Gastroenterol 80:290–293, 1985
Gustavsson S, Adami H-O, Lööf L, Nyberg A, Nyrén O: Rapid healing of duodenal ulcers with omeprazole: Doubleblind dose-comparative trial Lancet 2:124–125, 1983
Lööf L, Adami H-O, Gustavsson S, Nyberg A, Nyrén O, Lundborg P: Omeprazole: No evidence for frequent hepatic reactions. Lancet 1:1347–1348, 1984
Sölvell L: Safety aspects of omeprazole. Scand J Gastroenterol 21(suppl 118):129–133, 1986
Hui WM, Lam SK, Lau WY, Branicki FJ, Lok ASF, Ng MMT, Lai CL, Poon GP: Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse — a randomized double-blind study with weekly endoscopic assessment. J Gastroenterol Hepatol 4(suppl 2):35–43, 1989
Herting RL, Clay GA: Overview of clinical safety with misoprostol. Dig Dis Sci 30(suppl 11):185S-193S, 1985
Richter JM, Colditz GA, Huse DM, Delea TE, Oster G: Cimetidine and adverse reactions: A meta analysis of randomised clinical trials of short term therapy. Am J Med 87:278–284, 1989
Grant SM, Langtry HD, Brogden RN: Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 37:801–870, 1989
Cloud ML: Safety of nizatidine in clinical trials conducted in the USA and Europe. Scand J Gastroenterol 22(suppl 136):29–36, 1987
Graham DY, Agrawal N, Roth SH: Prevention of NSAID-induced gastric ulcer with the synthetic prostaglandin, misoprostol — a multicentre, double-blind, placebo-controlled trial. Lancet 2:1277–1281, 1988
Meshkinpour H, Molinari MD, Gardner L, Berk JE, Hoehler FK: Cimetidine in the treatment of acute alcoholic pancreatitis. Gastroenterology 77:687–690, 1979
Hainaut P, Schapira M, Mugabo P, Cerulus G, Coche E: Cimetidine-induced acute pancreatitis. Rev Med Interne 8:516–518, 1987
Guo G, Levi R, Graver LM, Robertson DA, Gay WA: Inotropic effects of histamine in human myocardium: differentiation between positive and negative components. J Cardiovasc Pharmacol 6:1210–1215, 1984
Coruzzi G, Poli E, Fesani F, Medici D, Bertaccini G: Negative inotropic effect of some H2 receptor antagonists on the isolated human atria. Experientia 39:1284–1286, 1983
Smith CL, Bardgett DM, Hunter JM: Haemodynamic effects of cimetidine or ranitidine iv. Br J Anaesth 59:1397–1402, 1987
Jefferies DB, Vale JA: Cimetidine and bradycardia. Lancet 1:828, 1978
Zucchi M: Ranitidine-induced bradycardia. Lancet 2:160, 1982
Cohen J, Weetman AP, Dargie JH, Krikler DM: Life threatening arrhythmias and intravenous cimetidine. BMJ 2:768, 1979
Watson AJS, Watson R, Keogh JAB: Cimetidine induced arrhythmias. Ir J Med Sci 151:348, 1982
Baylack-Domengatroy E, Gallimard JF, Allal J, Rousseau G, Barraine R: Troubles de la conduction auriceoventriculaire sous ranitidine intra-veineuse. Ann Med Interne 138:140–141, 1987
Kirch W, Halabi H, Ohnhaus EE: Negative inotropic effects of famotidine. Lancet 2:684–685, 1987
Omote K, Namiki A, Nishikawa T, Hagiwar AT, Iwasaki H, Tsuchida H: Haemodynamic effects of famotidine and cimetidine in critically ill patients. Acta Anaesthesiol Scand 34:576–578, 1990.
Borow KM, Ehler D, Berlin RG, Neumann A: Influence of histamine receptors on basal left ventricular contractile tone in humans: Assessment using the H2-receptor antagonist famotidine and the beta adrenoceptor antagonist esmolol as pharmacologic probes. J Am Coll Cardiol 19:1229–1236, 1992
Picardo M, Santucci B: Urticaria from ranitidine. Contact Dermatitis 9:327–328, 1983
Parenti CM, Hoffman J: Hyperpyrexia associated with intravenous cimetidine therapy. Arch Intern Med 146:1821, 1986
Potter H, Byrne EB, Levobitz S: Fever after cimetidine and ranitidine. J Clin Gastroenterol 8:275, 1986
Watson AJS, Dalbow MH, Stachura I, et al.: Immunologic studies of cimetidine-induced nephropathy and polymyositis. N Engl J Med 308:142–145, 1983
Labeeuw M, Cabanne JE, Dubot P: Recurrent myalgias associated with cimetidine. Int J Clin Pharmacol Ther Toxicol 24:349, 1986
Allegri G, Pelligrini K, Dobrilla G: First-degree atrioventricular block in a young duodenal ulcer patient treated with a standard oral dose of ranitidine. Agents Actions 24:237, 1988
Atlay RD, Weekes AR: The treatment of gastrointestinal disease in pregnancy. Clin Obstet Gynaecol 13:335–347, 1986
Nelson MM, Forfar JO: Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. BMJ 1:523–527, 1971
Lewis JH, Weingold AAB: The Committee on FDA-Related Matters. GI drug column. The use of gastrointestinal drugs during pregnancy and lactation. Am J Gastroenterol 80:912–919, 1985
Berkowitz RL, Constan DR:In Handbook for Prescribing Medications during Pregnancy. Boston, Little, Brown & Co, 1981, pp 22–23
Anand S, Van Thiel DH: Prenatal and neonatal exposure to cimetidine results in gonadal and sexual dysfunction in adult males. Science 218:493–494, 1982
Brimblecombe RW, Duncan WAM, Durant GJ, Emmett JC, Ganellin CR, Leslie GB, Parsons ME: Characterization and development of cimetidine as a histamine H2 receptor antagonist. Gastroenterology 74:339–347, 1978
Parker S, Schade RR, Pohl CR, Gavaler JS, Van Thiel DH: Prenatal and neonatal exposure of male rat pups to cimetidine but not ranitidine adversely affects subsequent adult sexual functioning. Gastroenterology 86:675–680, 1984
Glade G, Saccar CL, Pereira GR: Cimetidine in pregnancy: Apparent transient liver impairment in the newborn. Am J Dis Child 134:87–88, 1980
Moir DD: Cimetidine, antacids, and pulmonary aspiration. Anesthesiology 59:81–83, 1983
McAuley DM, Moore J, Dundee JW, McCaughey W: Preliminary report on the use of ranitidine as an antacid in obstetrics. Ir J Med Sci 151:91–92, 1982
McNab MSP, Milne MK, Allison RH: Oral ranitidine in labour. Br J Anaesth 57:1040–1041, 1985
Colin Jones DG, Langman MJS, Lawson DH, Vessey MP: Cimetidine and gastric cancer; preliminary report from post marketing surveillance study. BMJ 285:1311–1313, 1982
Colin Jones DG, Langman MJS, Lawson DH, Vessey MP: Post marketing surveillance of the safety of cimetidine: 12 months mortality. BMJ 286:1713–1726, 1983
Colin Jones DG, Langman MJS, Lawson DH, Vessey MP: Post marketing surveillance of the safety of cimetidine: 12 months morbidity report. Q J Med 54:253–268, 1983
Colin Jones DG, Langman MJS, Lawson DH, Vessey MP: Post marketing surveillance of the safety of cimetidine: mortality during second, third and fourth years of follow up. BMJ 219:1084–1088, 1985
Colin Jones DG, Langman MJS, Lawson DH, Vessey MP: Review: Post marketing surveillance of the safety of cimetidine—the problems of data interpretation. Aliment Pharmacol Ther 1:167–177, 1987
Colin Jones DG, Langman MJS, Lawson DH, Logan FRA, Paterson KR, Vessey MP: Post marketing surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus. Q J Med 78:13–19, 1991
Langman MJS: Antisecretory drugs and gastric cancer. BMJ 290:1850–1852, 1985
Möller H, Lindvig K, Klefter R, Mosbech J, Möller Jensen O: Cancer occurrence in a cohort of patients treated with cimetidine. Gut 30:1558–1562, 1989
Ching MS, Mihaly GW, Morgan DJ, Date NM, Hardy KJ, Smallwood RA: Low clearance of cimetidine across the human placenta J Pharmacol Exp Ther 241:1006–1009, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smallwood, R.A., Berlin, R.G., Castagnoli, N. et al. Safety of acid-suppressing drugs. Digest Dis Sci 40 (Suppl 2), 63S–80S (1995). https://doi.org/10.1007/BF02214872
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02214872